By Peter Loftus Of DOW JONES NEWSWIRES Bristol-Myers Squibb Co. (BMY) has eliminated about 25% of its sales force for the antipsychotic drug Abilify, a spokesman for the drug maker said Friday...
By Peter Loftus Of DOW JONES NEWSWIRES Bristol-Myers Squibb Co. (BMY) has eliminated about 25% of its sales force for the antipsychotic Abilify, a spokesman for the drug maker said Friday. The job...
The E.U. granted marketing approval to a diabetes drug codeveloped by AstraZeneca PLC (AZN) and Bristol-Myers Squibb Co. (BMY), marking the first drug to be launched by the two together in Europe...
AstraZeneca PLC (AZN.LN), a pharmaceutical company, and Bristol-Myers Squibb Company (BMY), a bio-pharmaceutical company, announced Monday that the European Commission has granted marketing...
U.K. drug maker AstraZeneca PLC (AZN.LN) Friday said an experimental diabetes medicine being jointly developed with Bristol-Myers Squibb Co. (BMY) met its goals in a phase III trial. The...
By Peter Loftus Of DOW JONES NEWSWIRES Adding an experimental diabetes drug co-developed by AstraZeneca PLC (AZN) and Bristol-Myers Squibb Co. (BMY) to the drug metformin reduced a measure of...
French food and bottled-water company Danone SA (BN.FR) Tuesday denied market speculation that it is in discussions with Mead Johnson Nutrition Co. (MJN) or that it has hired any adviser or bank...
Conflicting study data about Merck KGaA's (MRK.XE) key cancer drug proved a rollercoaster for shares of the German pharmaceutical company Wednesday. Shares fell Wednesday afternoon after an...
Bristol-Myers Squibb Co. (BMY) said a late-phase trial of cancer drug Erbitux when combined with Folfiri extended median overall survival of metastatic colorectal cancer patients, compared to just...
German pharmaceutical company Merck KGaA (MRK.XE) shares rose Wednesday after the company said an independent study showed colon cancer patients lived three and a half months longer when its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.